Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Tariff Resilience Score: 0/10 (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600329 Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SHSE:600329
65 GF Score
Price ¥36.43
GF Value ¥23.63
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Tianjin Pharmaceutical Da Ren Tang Group Tariff Resilience Score?

Tianjin Pharmaceutical Da Ren Tang Group has the Tariff Resilience Score of 0, which implies that the company might have .

Tianjin Pharmaceutical Da Ren Tang Group has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Tianjin Pharmaceutical Da Ren Tang Group might have .


Tianjin Pharmaceutical Da Ren Tang Group  (SHSE:600329) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Tianjin Pharmaceutical Da Ren Tang Group Tariff Resilience Score Related Terms

SHSE:600329
65GF Score
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd SHSE:600329
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Overvalued in 2026?

Based on GuruFocus' analysis, Tianjin Pharmaceutical Da Ren Tang Group stock appears to be overvalued. The current stock price of ¥36.43 is trading 54.2% above its estimated GF Value™ of ¥23.63. GuruFocus considers Tianjin Pharmaceutical Da Ren Tang Group to be Significantly Overvalued.

Key valuation signals for SHSE:600329:

  • Tariff Resilience Score: 0
  • GF Value™: ¥23.63 vs. price of ¥36.43 (54.2% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the SHSE:600329 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Other Exchanges T14:Singapore2TZ:Germany
Address No. 17 Baidi Road, Darentang Building, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company is engaged in the production and sale of traditional Chinese medicine, Western medicine, healthcare products, and investment holding. It operates in two segments, namely the Chinese Medicine segment and the Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures Western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese medicine.
65GF Score

Get the complete analysis for SHSE:600329

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.43
Price
¥23.63
GF Value